Study: Cannabidiol Mitigates Parkinson’s Disease Symptoms

By Paul Armentano, NORML

The administration of cannabidiol (CBD), a nonpsychotropic cannabinoid, controls sleep disorders in patients with Parkinson’s diseasemmjplant (PD), according to a series of case summaries published in the Journal of Clinical Pharmacy and Therapeutics.

An international team of investigators from the University of Sao Paulo, Brazil and the University of Minnesota Medical School reported on the ingestion of CBD by four Parkinson’s disease patients with REM sleep behavior disorder (RBD) – a condition characterized by nightmares and active behavior during dreaming.

Read moreStudy: Cannabidiol Mitigates Parkinson’s Disease Symptoms

Cannabis May Provide Resillience Against Stress-Related Patholigies, According to New Study

Maintaining “robust” encendocannabinoid signaling – which can be done through through the intake of cannabinoids – may providecannabisbud protection against stress and stress-related disorders, according to a new study published in the journal Seminars in Immunology, and published online by the National Institute of Health.

According to the study, “CB1 receptor-endocannabinoid signaling is activated by stress and functions to buffer or dampen the behavioral and endocrine effects of acute stress.”

It continues; “Its role in regulation of neuronal responses is more complex. Chronic variable stress exposure reduces endocannabinoid-CB1 receptor signaling and it is hypothesized that the resultant deficiency in endocannabinoid signaling contributes to the negative consequences of chronic stress. On the other hand, repeated exposure to the same stress can sensitize CB1 receptor signaling, resulting in dampening of the stress response.”

Read moreCannabis May Provide Resillience Against Stress-Related Patholigies, According to New Study

New Study: Cannabinoid Deficiency Worsens Kidney Disease

A new study published in this month’s issue of the journal Kidney International, and published online by the U.S. National Institute of Healthkidney, has found that cannabinoid deficiency worsens diabetic nephropathy, a type of kidney disease, indicating that cannabinoid therapy may provide a treatment.

“A functionally active endocannabinoid system is present within the kidney”, begins the study’s abstract. “The cannabinoid receptor type 2 (CB2) is expressed by both inflammatory cells and podocytes, and its activation has beneficial effects in experimental diabetic nephropathy.” It continues; “To further explore the role of CB2 in diabetic nephropathy, we studied renal functional and structural abnormalities in streptozotocin-induced diabetic CB2 knockout mice.”

Read moreNew Study: Cannabinoid Deficiency Worsens Kidney Disease

New Study: Cannabis May Treat Atherosclerosis

A new study being published in next month’s issue of the journal Atherosclerosis, and published online early by the National Institute of Health, has found that activation of the body’s cannabinoid receptorscannobliss – something done naturally by cannabis – may provide a potential treatment option for atherosclerosis.

Atherosclerosis, also known as vascular disease, is a fairly common disorder that occurs when substances such as fat or cholesterol build up in the walls of arteries, forming plaques. Over time, this process can block the arteries and cause severe problems throughout the body.

Read moreNew Study: Cannabis May Treat Atherosclerosis